Molecular pathogenesis of follicular cell derived thyroid cancers

International Journal of Surgery

Volumn 8, Issue 3, 2010, Pages 186-193

  Parameswaran, Rajeev ^a   Brooks, Susan ^b   Sadler, Gregory Paul ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b OXFORD BROOKES UNIVERSITY   (United Kingdom)

Author keywords

Growth factors; Oncogenes; Thyroid; Tumours

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ADENYLATE CYCLASE; APOPTOSIS REGULATORY PROTEIN; B RAF KINASE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; DIACYLGLYCEROL; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR; INOSITOL 1,4,5 TRISPHOSPHATE; MITOCHONDRIAL DNA; MITOGEN ACTIVATED PROTEIN KINASE; NEUROTRANSMITTER; PHORBOL ESTER; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOLIPASE C; PROTEIN GRIM 19; PROTEIN P53; PROTEIN RET; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; SORAFENIB; THYROGLOBULIN; THYROTROPIN; THYROTROPIN RECEPTOR; TRANSCRIPTION FACTOR PAX8; UNCLASSIFIED DRUG; VANDETANIB; WNT PROTEIN;

ANAPLASTIC CARCINOMA; CARCINOGENESIS; CHROMOSOME ABERRATION; FOLLICULAR CARCINOMA; GENE ACTIVATION; GENE EXPRESSION; GENE MUTATION; HUMAN; LIGAND BINDING; LYMPH NODE METASTASIS; ONCOCYTOMA; ONCOGENE RAS; PAPILLARY CARCINOMA; PATHOGENESIS; PRIORITY JOURNAL; PROTO ONCOGENE; REVIEW; SIGNAL TRANSDUCTION; THYROID CANCER; THYROID CELL; THYROID FUNCTION; THYROIDECTOMY;

ADENOCARCINOMA, FOLLICULAR; ADENOMA, OXYPHILIC; CARCINOMA, PAPILLARY; HUMANS; THYROID NEOPLASMS;

EID: 77950594215     PISSN: 17439191     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijsu.2010.01.005     Document Type: Review

References (136)

1. Vini L., and Harmer C. Management of thyroid cancer. Lancet Oncol 3 7 (2002 Jul) 407-414
2. Reynolds R.M., Weir J., Stockton D.L., Brewster D.H., Sandeep T.C., and Strachan M.W. Changing trends in incidence and mortality of thyroid cancer in Scotland. Clin Endocrinol (Oxf) 62 2 (2005 Feb) 156-162
3. Albores-Saavedra J., Henson D.E., Glazer E., and Schwartz A.M. Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype-papillary, follicular, and anaplastic: a morphological and epidemiological study. Endocr Pathol 18 1 (2007) 1-7 Spring
4. Coclet J., Foureau F., Ketelbant P., Galand P., and Dumont J.E. Cell population kinetics in dog and human adult thyroid. Clin Endocrinol (Oxf) 31 6 (1989 Dec) 655-665
5. Dumont J.E., Maenhaut C., Pirson I., Baptist M., and Roger P.P. Growth factors controlling the thyroid gland. Baillieres Clin Endocrinol Metab 5 4 (1991 Dec) 727-754
6. Bidey S.P., Hill D.J., and Eggo M.C. Growth factors and goitrogenesis. J Endocrinol 160 3 (1999 Mar) 321-332
7. Studer H., Gerber H., Zbaeren J., and Peter H.J. Histomorphological and immunohistochemical evidence that human nodular goiters grow by episodic replication of multiple clusters of thyroid follicular cells. J Clin Endocrinol Metab 75 4 (1992 Oct) 1151-1158
8. Parma J., Duprez L., Van Sande J., Cochaux P., Gervy C., Mockel J., et al. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 365 6447 (1993 Oct 14) 649-651
9. Porcellini A., Fenzi G., and Avvedimento E.V. Mutations of thyrotropin receptor gene. J Mol Med 75 8 (1997 Aug) 567-575
10. Downward J., Yarden Y., Mayes E., Scrace G., Totty N., Stockwell P., et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 307 5951 (1984 Feb 9-15) 521-527
11. Sawyer S.T., and Cohen S. Enhancement of calcium uptake and phosphatidylinositol turnover by epidermal growth factor in A-431 cells. Biochemistry 20 21 (1981 Oct 13) 6280-6286
12. Heldin N.E., and Westermark B. Epidermal growth factor, but not thyrotropin, stimulates the expression of c-fos and c-myc messenger ribonucleic acid in porcine thyroid follicle cells in primary culture. Endocrinology 122 3 (1988 Mar) 1042-1046
13. Shaver J.K., Tezelman S., Siperstein A.E., Duh Q.Y., and Clark O.H. Thyroid-stimulating hormone activates phospholipase C in normal and neoplastic thyroid tissue. Surgery 114 6 (1993 Dec) 1064-1069
14. Takano T. Fetal cell carcinogenesis of the thyroid: theory and practice. Semin Cancer Biol 17 3 (2007 Jun) 233-240
15. Takano T. Fetal cell carcinogenesis of the thyroid: a hypothesis for better understanding of gene expression profile and genomic alternation in thyroid carcinoma. Endocr J 51 6 (2004 Dec) 509-515
16. Takano T., and Amino N. Cancer-specific mRNAs in thyroid carcinomas: detection, use, and their implication in thyroid carcinogenesis. Endocr J 49 2 (2002 Apr) 97-107
17. Nowell P.C. The clonal evolution of tumor cell populations. Science 194 4260 (1976 Oct 1) 23-28
18. Vogelstein B., Fearon E.R., Hamilton S.R., Kern S.E., Preisinger A.C., Leppert M., et al. Genetic alterations during colorectal-tumor development. N Engl J Med 319 9 (1988 Sep 1) 525-532
19. McConahey W.M., Hay I.D., Woolner L.B., van Heerden J.A., and Taylor W.F. Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc 61 12 (1986 Dec) 978-996
20. Furmanchuk A.W., Averkin J.I., Egloff B., Ruchti C., Abelin T., Schappi W., et al. Pathomorphological findings in thyroid cancers of children from the Republic of Belarus: a study of 86 cases occurring between 1986 ('post-Chernobyl') and 1991. Histopathology 21 5 (1992 Nov) 401-408
21. Nikiforov Y., and Gnepp D.R. Pediatric thyroid cancer after the Chernobyl disaster. Pathomorphologic study of 84 cases (1991-1992) from the Republic of Belarus. Cancer 74 2 (1994 Jul 15) 748-766
22. Williams E.D. The aetiology of thyroid tumours. Clin Endocrinol Metab 8 1 (1979 Mar) 193-207
23. Plail R.O., Bussey H.J., Glazer G., and Thomson J.P. Adenomatous polyposis: an association with carcinoma of the thyroid. Br J Surg 74 5 (1987 May) 377-380
24. Klugbauer S., Lengfelder E., Demidchik E.P., and Rabes H.M. High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident. Oncogene 11 12 (1995 Dec 21) 2459-2467
25. Jhiang S.M., and Mazzaferri E.L. The ret/PTC oncogene in papillary thyroid carcinoma. J Lab Clin Med 123 3 (1994 Mar) 331-337
26. Rabes H.M., Demidchik E.P., Sidorow J.D., Lengfelder E., Beimfohr C., Hoelzel D., et al. Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. Clin Cancer Res 6 3 (2000 Mar) 1093-1103
27. Jhiang S.M. The RET proto-oncogene in human cancers. Oncogene 19 49 (2000 Nov 20) 5590-5597
28. Alberti L., Carniti C., Miranda C., Roccato E., and Pierotti M.A. RET and NTRK1 proto-oncogenes in human diseases. J Cell Physiol 195 2 (2003 May) 168-186
29. Ichihara M., Murakumo Y., and Takahashi M. RET and neuroendocrine tumors. Cancer Lett 204 2 (2004 Feb 20) 197-211
30. Santoro M., Melillo R.M., and Fusco A. RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. Eur J Endocrinol 155 5 (2006 Nov) 645-653
31. Nikiforov Y.E., Rowland J.M., Bove K.E., Monforte-Munoz H., and Fagin J.A. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res 57 9 (1997 May 1) 1690-1694
32. Tallini G., Santoro M., Helie M., Carlomagno F., Salvatore G., Chiappetta G., et al. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res 4 2 (1998 Feb) 287-294
33. Crespo P., and Leon J. Ras proteins in the control of the cell cycle and cell differentiation. Cell Mol Life Sci 57 11 (2000 Oct) 1613-1636
34. Bos J.L. Ras oncogenes in human cancer: a review. Cancer Res 49 17 (1989 Sep 1) 4682-4689
35. Suarez H.G., Du Villard J.A., Caillou B., Schlumberger M., Tubiana M., Parmentier C., et al. Detection of activated ras oncogenes in human thyroid carcinomas. Oncogene 2 4 (1988 Apr) 403-406
36. Namba H., Gutman R.A., Matsuo K., Alvarez A., and Fagin J.A. H-ras protooncogene mutations in human thyroid neoplasms. J Clin Endocrinol Metab 71 1 (1990 Jul) 223-229
37. Zhu Z., Gandhi M., Nikiforova M.N., Fischer A.H., and Nikiforov Y.E. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol 120 1 (2003 Jul) 71-77
38. Di Cristofaro J., Marcy M., Vasko V., Sebag F., Fakhry N., Wynford-Thomas D., et al. Molecular genetic study comparing follicular variant versus classic papillary thyroid carcinomas: association of N-ras mutation in codon 61 with follicular variant. Hum Pathol 37 7 (2006 Jul) 824-830
39. Adeniran A.J., Zhu Z., Gandhi M., Steward D.L., Fidler J.P., Giordano T.J., et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 30 2 (2006 Feb) 216-222
40. Nikiforov Y.E. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocr Pathol 15 4 (2004) 319-327 Winter
41. Hara H., Fulton N., Yashiro T., Ito K., DeGroot L.J., and Kaplan E.L. N-ras mutation: an independent prognostic factor for aggressiveness of papillary thyroid carcinoma. Surgery 116 6 (1994 Dec) 1010-1016
42. Sithanandam G., Druck T., Cannizzaro L.A., Leuzzi G., Huebner K., and Rapp U.R. B-raf and a B-raf pseudogene are located on 7q in man. Oncogene 7 4 (1992 Apr) 795-799
43. Mercer K.E., and Pritchard C.A. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 1653 1 (2003 Jun 5) 25-40
44. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., et al. Mutations of the BRAF gene in human cancer. Nature 417 6892 (2002 Jun 27) 949-954
45. Namba H., Nakashima M., Hayashi T., Hayashida N., Maeda S., Rogounovitch T.I., et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 88 9 (2003 Sep) 4393-4397
46. Kim K.H., Kang D.W., Kim S.H., Seong I.O., and Kang D.Y. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 45 5 (2004 Oct 31) 818-821
47. Kimura E.T., Nikiforova M.N., Zhu Z., Knauf J.A., Nikiforov Y.E., and Fagin J.A. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63 7 (2003 Apr 1) 1454-1457
48. Cohen Y., Xing M., Mambo E., Guo Z., Wu G., Trink B., et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95 8 (2003 Apr 16) 625-627
49. Ciampi R., and Nikiforov Y.E. Alterations of the BRAF gene in thyroid tumors. Endocr Pathol 16 3 (2005) 163-172 Fall
50. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 12 2 (2005 Jun) 245-262
51. Nikiforova M.N., Kimura E.T., Gandhi M., Biddinger P.W., Knauf J.A., Basolo F., et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88 11 (2003 Nov) 5399-5404
52. Bottaro D.P., Rubin J.S., Faletto D.L., Chan A.M., Kmiecik T.E., Vande Woude G.F., et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251 4995 (1991 Feb 15) 802-804
53. Bussolino F., Di Renzo M.F., Ziche M., Bocchietto E., Olivero M., Naldini L., et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 119 3 (1992 Nov) 629-641
54. Di Renzo M.F., Olivero M., Ferro S., Prat M., Bongarzone I., Pilotti S., et al. Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. Oncogene 7 12 (1992 Dec) 2549-2553
55. Nardone H.C., Ziober A.F., LiVolsi V.A., Mandel S.J., Baloch Z.W., Weber R.S., et al. c-Met expression in tall cell variant papillary carcinoma of the thyroid. Cancer 98 7 (2003 Oct 1) 1386-1393
56. Harach H.R., Escalante D.A., Onativia A., Lederer Outes J., Saravia Day E., and Williams E.D. Thyroid carcinoma and thyroiditis in an endemic goitre region before and after iodine prophylaxis. Acta Endocrinol (Copenh) 108 1 (1985 Jan) 55-60
57. Evans H.L., and Vassilopoulou-Sellin R. Follicular and Hurthle cell carcinomas of the thyroid: a comparative study. Am J Surg Pathol 22 12 (1998 Dec) 1512-1520
58. Liu Z., Hou P., Ji M., Guan H., Studeman K., Jensen K., et al. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 93 8 (2008 Aug) 3106-3116
59. Wright P.A., Williams E.D., Lemoine N.R., and Wynford-Thomas D. Radiation-associated and 'spontaneous' human thyroid carcinomas show a different pattern of ras oncogene mutation. Oncogene 6 3 (1991 Mar) 471-473
60. Rivera M., Ricarte-Filho J., Patel S., Tuttle M., Shaha A., Shah J.P., et al. Encapsulated thyroid tumors of follicular cell origin with high grade features (high mitotic rate/tumor necrosis): a clinicopathologic and molecular study. Hum Pathol (2009 Nov 12)
61. Miller K.A., Yeager N., Baker K., Liao X.H., Refetoff S., and Di Cristofano A. Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo. Cancer Res 69 8 (2009 Apr 15) 3689-3694
62. Wang H.M., Huang Y.W., Huang J.S., Wang C.H., Kok V.C., Hung C.M., et al. Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma. Ann Surg Oncol 14 10 (2007 Oct) 3011-3018
63. Vitagliano D., Portella G., Troncone G., Francione A., Rossi C., Bruno A., et al. Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas. Oncogene 25 39 (2006 Aug 31) 5467-5474
64. Garcia-Rostan G., Zhao H., Camp R.L., Pollan M., Herrero A., Pardo J., et al. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 21 17 (2003 Sep 1) 3226-3235
65. Esposito C., Miccadei S., Saiardi A., and Civitareale D. PAX 8 activates the enhancer of the human thyroperoxidase gene. Biochem J 331 Pt 1 (1998 Apr 1) 37-40
66. Fabbro D., Pellizzari L., Mercuri F., Tell G., and Damante G. Pax-8 protein levels regulate thyroglobulin gene expression. J Mol Endocrinol 21 3 (1998 Dec) 347-354
67. Kroll T.G., Sarraf P., Pecciarini L., Chen C.J., Mueller E., Spiegelman B.M., et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science 289 5483 (2000 Aug 25) 1357-1360
68. Nikiforova M.N., Biddinger P.W., Caudill C.M., Kroll T.G., and Nikiforov Y.E. PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol 26 8 (2002 Aug) 1016-1023
69. Marques A.R., Espadinha C., Catarino A.L., Moniz S., Pereira T., Sobrinho L.G., et al. Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 87 8 (2002 Aug) 3947-3952
70. Martelli M.L., Iuliano R., Le Pera I., Sama I., Monaco C., Cammarota S., et al. Inhibitory effects of peroxisome proliferator-activated receptor gamma on thyroid carcinoma cell growth. J Clin Endocrinol Metab 87 10 (2002 Oct) 4728-4735
71. French C.A., Alexander E.K., Cibas E.S., Nose V., Laguette J., Faquin W., et al. Genetic and biological subgroups of low-stage follicular thyroid cancer. Am J Pathol 162 4 (2003 Apr) 1053-1060
72. Lacroix L., Lazar V., Michiels S., Ripoche H., Dessen P., Talbot M., et al. Follicular thyroid tumors with the PAX8-PPARgamma1 rearrangement display characteristic genetic alterations. Am J Pathol 167 1 (2005 Jul) 223-231
73. Marques A.R., Espadinha C., Frias M.J., Roque L., Catarino A.L., Sobrinho L.G., et al. Underexpression of peroxisome proliferator-activated receptor (PPAR)gamma in PAX8/PPARgamma-negative thyroid tumours. Br J Cancer 91 4 (2004 Aug 16) 732-738
74. Sahin M., Allard B.L., Yates M., Powell J.G., Wang X.L., Hay I.D., et al. PPARgamma staining as a surrogate for PAX8/PPARgamma fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopathological diagnostic value. J Clin Endocrinol Metab 90 1 (2005 Jan) 463-468
75. Weaver B.A., and Cleveland D.W. Aneuploidy: instigator and inhibitor of tumorigenesis. Cancer Res 67 21 (2007 Nov 1) 10103-10105
76. Schelfhout L.J., Cornelisse C.J., Goslings B.M., Hamming J.F., Kuipers-Dijkshoorn N.J., van de Velde C.J., et al. Frequency and degree of aneuploidy in benign and malignant thyroid neoplasms. Int J Cancer 45 1 (1990 Jan 15) 16-20
77. Grant C.S., Hay I.D., Ryan J.J., Bergstralh E.J., Rainwater L.M., and Goellner J.R. Diagnostic and prognostic utility of flow cytometric DNA measurements in follicular thyroid tumors. World J Surg 14 3 (1990 May-Jun) 283-289 discussion 9-90
78. Cusick E.L., Ewen S.W., Krukowski Z.H., and Matheson N.A. DNA aneuploidy in follicular thyroid neoplasia. Br J Surg 78 1 (1991 Jan) 94-96
79. Oyama T., Vickery Jr. A.L., Preffer F.I., and Colvin R.B. A comparative study of flow cytometry and histopathologic findings in thyroid follicular carcinomas and adenomas. Hum Pathol 25 3 (1994 Mar) 271-275
80. Roque L., Serpa A., Clode A., Castedo S., and Soares J. Significance of trisomy 7 and 12 in thyroid lesions with follicular differentiation: a cytogenetic and in situ hybridization study. Lab Invest 79 4 (1999 Apr) 369-378
81. Eng C. The role of PTEN, a phosphatase gene, in inherited and sporadic nonmedullary thyroid tumors. Recent Prog Horm Res 54 (1999) 441-452 discussion 53
82. Halachmi N., Halachmi S., Evron E., Cairns P., Okami K., Saji M., et al. Somatic mutations of the PTEN tumor suppressor gene in sporadic follicular thyroid tumors. Genes Chromosomes Cancer 23 3 (1998 Nov) 239-243
83. Dahia P.L., Marsh D.J., Zheng Z., Zedenius J., Komminoth P., Frisk T., et al. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res 57 21 (1997 Nov 1) 4710-4713
84. Hsieh M.C., Lin S.F., Shin S.J., Liu T.C., Chang J.G., and Lee J.P. Mutation analysis of PTEN/MMAC 1 in sporadic thyroid tumors. Kaohsiung J Med Sci 16 1 (2000 Jan) 9-12
85. Gimm O., Chi H., Dahia P.L., Perren A., Hinze R., Komminoth P., et al. Somatic mutation and germline variants of MINPP1, a phosphatase gene located in proximity to PTEN on 10q23.3, in follicular thyroid carcinomas. J Clin Endocrinol Metab 86 4 (2001 Apr) 1801-1805
86. Hou P., Liu D., Shan Y., Hu S., Studeman K., Condouris S., et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res 13 4 (2007 Feb 15) 1161-1170
87. Frisk T., Foukakis T., Dwight T., Lundberg J., Hoog A., Wallin G., et al. Silencing of the PTEN tumor-suppressor gene in anaplastic thyroid cancer. Genes Chromosomes Cancer 35 1 (2002 Sep) 74-80
88. Bruni P., Boccia A., Baldassarre G., Trapasso F., Santoro M., Chiappetta G., et al. PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells mediated by p27kip1. Oncogene 19 28 (2000 Jun 29) 3146-3155
89. Bachman K.E., Argani P., Samuels Y., Silliman N., Ptak J., Szabo S., et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3 8 (2004 Aug) 772-775
90. Levine D.A., Bogomolniy F., Yee C.J., Lash A., Barakat R.R., Borgen P.I., et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 11 8 (2005 Apr 15) 2875-2878
91. Wang Y., Hou P., Yu H., Wang W., Ji M., Zhao S., et al. High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors. J Clin Endocrinol Metab 92 6 (2007 Jun) 2387-2390
92. Hou P., Ji M., and Xing M. Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer 113 9 (2008 Nov 1) 2440-2447
93. Gonzalez-Campora R., Herrero-Zapatero A., Lerma E., Sanchez F., and Galera H. Hurthle cell and mitochondrion-rich cell tumors. A clinicopathologic study. Cancer 57 6 (1986 Mar 15) 1154-1163
94. Arganini M., Behar R., Wu T.C., Straus II F., McCormick M., DeGroot L.J., et al. Hurthle cell tumors: a twenty-five-year experience. Surgery 100 6 (1986 Dec) 1108-1115
95. Maximo V., Soares P., Lima J., Cameselle-Teijeiro J., and Sobrinho-Simoes M. Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hurthle cell tumors. Am J Pathol 160 5 (2002 May) 1857-1865
96. Savagner F., Franc B., Guyetant S., Rodien P., Reynier P., and Malthiery Y. Defective mitochondrial ATP synthesis in oxyphilic thyroid tumors. J Clin Endocrinol Metab 86 10 (2001 Oct) 4920-4925
97. Kalvakolanu D.V. The GRIMs: a new interface between cell death regulation and interferon/retinoid induced growth suppression. Cytokine Growth Factor Rev 15 2-3 (2004 Apr-Jun) 169-194
98. Katoh R., Harach H.R., and Williams E.D. Solitary, multiple, and familial oxyphil tumours of the thyroid gland. J Pathol 186 3 (1998 Nov) 292-299
99. Maximo V., Botelho T., Capela J., Soares P., Lima J., Taveira A., et al. Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid. Br J Cancer 92 10 (2005 May 23) 1892-1898
100. Wada N., Duh Q.Y., Miura D., Brunaud L., Wong M.G., and Clark O.H. Chromosomal aberrations by comparative genomic hybridization in hurthle cell thyroid carcinomas are associated with tumor recurrence. J Clin Endocrinol Metab 87 10 (2002 Oct) 4595-4601
101. Cheung C.C., Ezzat S., Ramyar L., Freeman J.L., and Asa S.L. Molecular basis off hurthle cell papillary thyroid carcinoma. J Clin Endocrinol Metab 85 2 (2000 Feb) 878-882
102. Ain K.B. Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid 8 8 (1998 Aug) 715-726
103. Are C., and Shaha A.R. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 13 4 (2006 Apr) 453-464
104. McIver B., Hay I.D., Giuffrida D.F., Dvorak C.E., Grant C.S., Thompson G.B., et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 130 6 (2001 Dec) 1028-1034
105. Kaghad M., Bonnet H., Yang A., Creancier L., Biscan J.C., Valent A., et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90 4 (1997 Aug 22) 809-819
106. Schmale H., and Bamberger C. A novel protein with strong homology to the tumor suppressor p53. Oncogene 15 11 (1997 Sep) 1363-1367
107. Hollstein M., Shomer B., Greenblatt M., Soussi T., Hovig E., Montesano R., et al. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res 24 1 (1996 Jan 1) 141-146
108. Dobashi Y., Sugimura H., Sakamoto A., Mernyei M., Mori M., Oyama T., et al. Stepwise participation of p53 gene mutation during dedifferentiation of human thyroid carcinomas. Diagn Mol Pathol 3 1 (1994 Mar) 9-14
109. Fagin J.A., Matsuo K., Karmakar A., Chen D.L., Tang S.H., and Koeffler H.P. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91 1 (1993 Jan) 179-184
110. Pollina L., Pacini F., Fontanini G., Vignati S., Bevilacqua G., and Basolo F. bcl-2, p53 and proliferating cell nuclear antigen expression is related to the degree of differentiation in thyroid carcinomas. Br J Cancer 73 2 (1996 Jan) 139-143
111. Wynford-Thomas D. Molecular genetics of thyroid cancer. Trends Endocrinol Metab 4 7 (1993 Sep) 224-232
112. Donghi R., Longoni A., Pilotti S., Michieli P., Della Porta G., and Pierotti M.A. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest 91 4 (1993 Apr) 1753-1760
113. Blagosklonny M.V., Giannakakou P., Wojtowicz M., Romanova L.Y., Ain K.B., Bates S.E., et al. Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 83 7 (1998 Jul) 2516-2522
114. Ceraline J., Deplanque G., Noel F., Natarajan-Ame S., Bergerat J.P., and Klein-Soyer C. Sensitivity to cisplatin treatment of human K1 thyroid carcinoma cell lines with altered p53 function. Cancer Chemother Pharmacol 51 1 (2003 Jan) 91-95
115. Portella G., Pacelli R., Libertini S., Cella L., Vecchio G., Salvatore M., et al. ONYX-015 enhances radiation-induced death of human anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab 88 10 (2003 Oct) 5027-5032
116. Portella G., Scala S., Vitagliano D., Vecchio G., and Fusco A. ONYX-015, an E1B gene-defective adenovirus, induces cell death in human anaplastic thyroid carcinoma cell lines. J Clin Endocrinol Metab 87 6 (2002 Jun) 2525-2531
117. Garcia-Rostan G., Costa A.M., Pereira-Castro I., Salvatore G., Hernandez R., Hermsem M.J., et al. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res 65 22 (2005 Nov 15) 10199-10207
118. Santarpia L., El-Naggar A.K., Cote G.J., Myers J.N., and Sherman S.I. Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab 93 1 (2008 Jan) 278-284
119. Fukushima T., and Takenoshita S. Roles of RAS and BRAF mutations in thyroid carcinogenesis. Fukushima J Med Sci 51 2 (2005 Dec) 67-75
120. Costa A.M., Herrero A., Fresno M.F., Heymann J., Alvarez J.A., Cameselle-Teijeiro J., et al. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma. Clin Endocrinol (Oxf) 68 4 (2008 Apr) 618-634
121. Soares P., Trovisco V., Rocha A.S., Feijao T., Rebocho A.P., Fonseca E., et al. BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. Virchows Arch 444 6 (2004 Jun) 572-576
122. Begum S., Rosenbaum E., Henrique R., Cohen Y., Sidransky D., and Westra W.H. BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Mod Pathol 17 11 (2004 Nov) 1359-1363
123. Morin P.J. beta-catenin signaling and cancer. Bioessays 21 12 (1999 Dec) 1021-1030
124. Garcia-Rostan G., Camp R.L., Herrero A., Carcangiu M.L., Rimm D.L., and Tallini G. Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol 158 3 (2001 Mar) 987-996
125. Miyake N., Maeta H., Horie S., Kitamura Y., Nanba E., Kobayashi K., et al. Absence of mutations in the beta-catenin and adenomatous polyposis coli genes in papillary and follicular thyroid carcinomas. Pathol Int 51 9 (2001 Sep) 680-685
126. Garcia-Rostan G., Tallini G., Herrero A., D'Aquila T.G., Carcangiu M.L., and Rimm D.L. Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res 59 8 (1999 Apr 15) 1811-1815
127. Inohara H., Honjo Y., Yoshii T., Akahani S., Yoshida J., Hattori K., et al. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Cancer 85 11 (1999 Jun 1) 2475-2484
128. Weinberger P.M., Adam B.L., Gourin C.G., Moretz III W.H., Bollag R.J., Wang B.Y., et al. Association of nuclear, cytoplasmic expression of galectin-3 with beta-catenin/Wnt-pathway activation in thyroid carcinoma. Arch Otolaryngol Head Neck Surg 133 5 (2007 May) 503-510
129. Aratake Y., Nomura H., Kotani T., Marutsuka K., Kobayashi K., Kuma K., et al. Coexistent anaplastic and differentiated thyroid carcinoma: an immunohistochemical study. Am J Clin Pathol 125 3 (2006 Mar) 399-406
130. Nikiforova M.N., Chiosea S.I., and Nikiforov Y.E. MicroRNA expression profiles in thyroid tumors. Endocr Pathol 20 2 (2009) 85-91 Summer
131. Sapio M.R., Posca D., Raggioli A., Guerra A., Marotta V., Deandrea M., et al. Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings. Clin Endocrinol (Oxf) 66 5 (2007 May) 678-683
132. Carlomagno F., Vitagliano D., Guida T., Ciardiello F., Tortora G., Vecchio G., et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62 24 (2002 Dec 15) 7284-7290
133. Hong D.S., Sebti S.M., Newman R.A., Blaskovich M.A., Ye L., Gagel R.F., et al. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res 15 22 (2009 Nov 15) 7061-7068
134. Preto A., Goncalves J., Rebocho A.P., Figueiredo J., Meireles A.M., Rocha A.S., et al. Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations. BMC Cancer 9 (2009) 387
135. Kim D.W., Jo Y.S., Jung H.S., Chung H.K., Song J.H., Park K.C., et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 91 10 (2006 Oct) 4070-4076
136. Ouyang B., Knauf J.A., Smith E.P., Zhang L., Ramsey T., Yusuff N., et al. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res 12 6 (2006 Mar 15) 1785-1793